anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Although high blood sugar and risk of heart disease are the most well-known health effects of type 2 diabetes (T2DM), nonalcoholic fatty liver disease (NAFLD), in which too much fat accumulates in the liver, has come to be recognized as another important complication. Unchecked, NAFLD can progress to severe liver inflammation, liver failure, and even liver cancer. The investigators suspect that high levels of the blood sugar-lowering hormone insulin leads to excessive fat production by the liver, and so lowering insulin levels might help to improve NAFLD. In order to answer this question, the investigators will recruit people at risk for T2DM and NAFLD to perform a "pancreatic clamp" - a procedure in which the body's production of insulin is temporarily shut off and then replaced at the same or lower levels. Again, the investigators expect that lowering insulin levels will lower fat production. Because this is a new research approach, the investigators first need to understand how lowering insulin levels affects blood sugar. Research participants in this pilot study will therefore undergo two pancreatic clamps in random order: one roughly maintaining their own internal ("basal") insulin level and one in which the investigators lower that basal insulin level by up to 50%. In each case, the investigators will observe the absolute and relative changes in blood sugar and the levels of certain fats as the investigators change the insulin level. Once the investigators have found a lower insulin level that they can safely maintain, the investigators will go on to study its effect on fat production in a later study.
Methods for stimulating proliferation of cells in the epidermis and dermis of mammalian skin are disclosed. The methods comprise the step of administering to an area of the skin a composition comprising a therapeutically effective amount of human placental alkaline phosphatase, or an active derivative. The composition can be administered topically or by injection. The invention also provides a regimen for restoring or maintaining the strength and thickness of aging skin, comprising periodically administering a composition by topical application. The invention further provides methods for stimulating proliferation of cells in the epidermis and dermis of transplanted skin. A composition for topical application is also provided by the invention.
Alzheimer's Disease (AD) and Frontotemporal Dementia (FTD) are the two major neurodegenerative diseases with distinct clinical and neuropathological profiles. The aim of this report is to conduct a population-based investigation in well-characterized APP, PSEN1, PSEN2, MAPT, GRN, and C9orf72 mutation carriers/pedigrees from the north, the center, and the south of Italy. We retrospectively analyzed the data of 467 Italian individuals. We identified 21 different GRN mutations, 20 PSEN1, 11 MAPT, 9 PSEN2, and 4 APP. Moreover, we observed geographical variability in mutation frequencies by looking at each cohort of participants, and we observed a significant difference in age at onset among the genetic groups. Our study provides evidence that age at onset is influenced by the genetic group. Further work in identifying both genetic and environmental factors that modify the phenotypes in all groups is needed. Our study reveals Italian regional differences among the most relevant AD/FTD causative genes and emphasizes how the collaborative studies in rare diseases can provide new insights to expand knowledge on genetic/epigenetic modulators of age at onset.
FIELD: medicine, microbiology, vaccine prophylaxis. SUBSTANCE: method involves addition of 0.1 mcg of synthetic polyelectrolyte - polyoxydonium dissolved in phosphate buffer to 0.1 mcg of protective antigen (by protein level) followed by stirring on magnetic mixer at 37 C for 20 min and then at 3-6 C for 3 h and filtration through filter (pore diameter is 0.45 mcm). Invention can be used in construction of areactogenic whooping cough vaccine preparation. Invention ensures to obtain conjugated protective whooping cough antigen based on synthetic carrier - polyoxydonium exhibiting high immunogenic properties (95% of viability). EFFECT: improved method of preparing, high quality and properties of antigen. 1 tbl
The present invention relates to fengbao antitussive liquid, which is characterized in that the medicine is produced with the following raw materials in weight proportions: 8 to 12 proportions of honey, 0.5 to 1.5 proportions of royal jelly, 1 to 3 proportions of honeycomb and 6 to 10 proportions of propolis. The honeycomb is dissolved and filtered after 5 to 15 proportions of water is added, the honey, the royal jelly and the propolis are put into the dissolved and filtered liquid for mixing. Then the finished medicine can be obtained. The present invention has the remarkable advantages that: the 'fengbao antitussive liquid' produced by adopting the method provided by the present invention can be used for curing a variety of coughs with simple method. The 'fengbao antitussive liquid' is rapid in relieving a cough and good in effect without side effect. Patients suffer from no pain. The cost is low. The 'fengbao antitussive liquid' is suitable for mass consumers.
Experiment 6 will test the effects of music with aggressive versus prosocial lyrics on aggressive driving. The tempo of the music will also be manipulated because it might influence arousal levels. After giving their consent, participants (N=150, n=30 per group) will complete the personal variables (see Experiment 1). Music will be played over the car's sound system. Participants will be randomly assigned to one of five conditions: (1) violent lyrics / upbeat tempo, (2) violent lyrics / calm tempo, (3) prosocial lyrics / upbeat tempo, (4) prosocial lyrics / calm tempo, or (5) no music control. After participants complete the driving scenario, they will complete measures of state and hostile appraisals, and will be debriefed.
Cryptosporidium parvum, an intracellular protozoan parasite, is a frequent cause of chronic diarrhea in HIV-infected patients, causing significant morbidity and mortality. Highly effective antiparasitic treatment for this infection is not currently available. Paromomycin and azithromycin have some efficacy and have been used in combination in a small number of patients. Immune reconstitution with highly active antiretroviral therapy appears to be the most effective therapy, but this is not possible for all patients. Interferon gamma expression is strongly associated with control of cryptosporidiosis, and IL-12 is the cytokine primarily responsible for stimulation of interferon gamma expression in vivo. It is hoped that treatment with recombinant human IL-12 can result in stimulation of an intestinal cytokine response in AIDS patients with cryptosporidiosis and that response combined with chemotherapy can lead to the elimination of detectable numbers of Cryptosporidium oocysts from the stools.

All patients receive azithromycin and paromomycin, and patients are randomized to add either IL-12 or placebo. IL-12 (or placebo) injections are given twice a week. Patients take their study medications for 4 weeks. During this time, they will be asked to record bowel movements and any symptoms they experience. Patients return to the clinic at least twice a week to receive IL-12 (or placebo) injections. At Weeks 2 and 4, patients are seen by one of the principal investigators. Blood samples are obtained for viral load measurements and CD4 count, as well as routine urinalysis. Patients undergo upper endoscopy with jejunal biopsy and colonoscopy with ileal biopsy between Weeks 2 and 4 of therapy for assays of intestinal cytokine expression. A final clinic visit occurs 12 weeks post-therapy for a physical exam and blood tests.
FIELD: medicine, biochemistry. SUBSTANCE: invention is related to the long-term modification and regulation of lipid and carbohydrate metabolism, obesity decrease, decrease of resistance to insulin, hyperinsulinemia and hyperglycaemia or both (typical traits of insulin-nondepending diabetes, diabetes of type II). Method involves the administration of bromocriptine (dopamine against) to human or animals by oral, sublingual or parenteral routes. Bromocriptine is administrated at the definite limited time of day depending on the normal circadian rhythm in insulin-resistant and insulin-sensitive representatives of related species. Resistance to insulin, hyperinsulinemia and hyperglycaemia or both can be controlled in human on the long-term basis of proposed treatment since short-term diurnal preparation administration corrects the hormonal "schedule" in brain nervous centers that makes the long-term effect. EFFECT: improved method of treatment.
Participants with age 18 and over who received a first prescription of single-ingredient paracetamol or ibuprofen in 2012 will be enrolled. Their status with respect to prior gastrointestinal bleeding, myocardial infarction, stroke, or kidney disease will be assessed based on the presence or absence of a diagnosis in the 2 years prior to the index date. This observational study will evaluate whether new users of paracetamol have a higher prevalence of certain conditions (gastrointestinal bleeding, myocardial infarction, stroke or kidney disease) in their history when compared to new users of ibuprofen, propensity scores and outcome models.
In an embodiment, the present disclosure relates to a targeting platform that includes a targeted delivery system including an agent. In some embodiments, the targeted delivery system is modified by fluorination. In some embodiments, the targeted delivery system is electrically charge neutral. In a further embodiment, the present disclosure relates to a method that includes fluorinating a targeting compound with a fluorinating reagent and loading an agent with the fluorinated targeting compound to thereby form a micelle. In an additional embodiment, the present disclosure relates to a targeting platform that includes a fluorinated polymeric system including an agent. In another embodiment, the present disclosure relates to a method that includes fluorinating a targeting compound with a fluorinating reagent and loading an agent with the fluorinated targeting compound to thereby form a micelle. Additionally, the method can include administering the fluorinated targeting compound to a subject.
Background: Colorectal cancer (CRC) exhibits molecular and morphological diversity, involving genetic, epigenetic alterations, and disruptions in signaling pathways. This necessitates a comprehensive review synthesizing recent advancements in molecular mechanisms, established biomarkers, as well as emerging ones like CDX2 for enhanced CRC assessment. Material and Methods: This review analyzes the last decade's literature and current guidelines to study CRC's molecular intricacies. It extends the analysis beyond traditional biomarkers to include emerging ones like CDX2, examining their interaction with carcinogenic mechanisms and molecular pathways, alongside reviewing current testing methodologies. Results: A multi-biomarker strategy, incorporating both traditional and emerging biomarkers like CDX2, is crucial for optimizing CRC management. This strategy elucidates the complex interaction between biomarkers and the tumor's molecular pathways, significantly influencing prognostic evaluations, therapeutic decision-making, and paving the way for personalized medicine in CRC. Conclusions: This review proposes CDX2 as an emerging prognostic biomarker and emphasizes the necessity of thorough molecular profiling for individualized treatment strategies. By enhancing CRC treatment approaches and prognostic evaluation, this effort marks a step forward in precision oncology, leveraging an enriched understanding of tumor behavior.
PURPOSE:To obtain an excellent backing material for denture base exhibiting excellent gelation and extremely small lowering of elasticity and dimensional shrinkage, by adding a plasticizer to a homopolymer or copolymer of ethyl methacrylate used as a powder component. CONSTITUTION:The objective backing material for denture base is produced by compounding (A) a mixture of a homopolymer or copolymer of at least ethyl methacrylate and 5-30wt% plasticizer (especially preferably a phthalate such as dimethyl phthalate, diethyl phthalate, etc.) as a powder component and (B) 50-200pts.wt. of a liquid component comprising a plasticizer based on 100pts.wt. of the powder component. The mixing of ethyl methacrylate polymer and a plasticizer used as the powder component can be facilitated by using a solvent. The material is further added with 0.5-30wt% inorganic filler to improve the fluidity of the polymer and the operation efficiency of kneading. EFFECT:The material is free from disagreeable taste and applicable by simple operation.
In this arm participants are followed up and no medications be used until BP becomes ≥ 140 mm Hg systolic and/or 90 mm Hg diastolic. Medications are determined by investigators in lines with recommendations by current Chinese guidelines to decrease BP to lower than 140 mm Hg systolic and to lower than 90 mm Hg diastolic.
208,690. Aktiebolaget Pharmacia. Dec. 21, 1922, [Convention date]. Void [Published under Sect. 91 of the Act]. Lotions.-A preparation for use more particularly in the treatment of otitis, comprises a concentrated sugar solution to which antiseptic and anµsthetic substances have been added. Preferably a monosaccharide solution is used, and a suitable solution may comprise glucose and fructose mixed so that no crystallization occurs at 10‹ C., the mixture being dissolved in a little water and filtered. To the monosaccharide solution thus obtained are added an aqueous solution of adrenalin or suprarenin, cocaine, and antiseptic substances such as isoamylhydrocupreine, phenols, or cresols. An example of suitable proportions is given.
This group will consist of 15 patients with locally advanced HNSCC of the oral cavity, larynx or hypopharynx presenting with adenopathy ≥ 1 cm where the recommended treatment is surgical resection of the primary malignancy with bilateral neck dissection. These patients will receive a DCE-CT scan of the head and neck prior to surgery.
Senescence is a physiological and pathological cellular program triggered by various types of cellular stress. Senescent cells exhibit multiple characteristic changes. Among them, the characteristic flattened and enlarged morphology exhibited in senescent cells is observed regardless of the stimuli causing the senescence. Several studies have provided important insights into pro-adhesive properties of cellular senescence, suggesting that cell adhesion to the extracellular matrix (ECM), which is involved in characteristic morphological changes, may play pivotal roles in cellular senescence. Matricellular proteins, a group of structurally unrelated ECM molecules that are secreted into the extracellular environment, have the unique ability to control cell adhesion to the ECM by binding to cell adhesion receptors, including integrins. Recent reports have certified that matricellular proteins are closely involved in cellular senescence. Through this biological function, matricellular proteins are thought to play important roles in the pathogenesis of age-related diseases, including fibrosis, osteoarthritis, intervertebral disc degeneration, atherosclerosis, and cancer. This review outlines recent studies on the role of matricellular proteins in inducing cellular senescence. We highlight the role of integrin-mediated signaling in inducing cellular senescence and provide new therapeutic options for age-related diseases targeting matricellular proteins and integrins.
Neuropathic pain is a common pain syndrome, which seriously affects the quality of life of patients. The mechanism of neuropathic pain is complex. Peripheral tissue injury can trigger peripheral sensitization; however, what really plays a key role is the sensitization of the central nervous system. Central sensitization is a key factor in the perception of chronic pain. Central sensitization refers to the increased sensitivity of the central nervous system to pain treatment, which is related to the change of the functional connection mode of the neural network. The current study aims to reveal the basic molecular mechanisms of central sensitization, including the involvement of P2 purine X4 receptor and brain-derived neurotrophic factor. In terms of treatment, although there are drugs and physical therapy, the accuracy of targeting is limited and the efficacy needs to be further improved. Future therapeutic strategies may involve the development of new drugs designed to specifically inhibit the central sensitization process. This article focuses on the effector molecules involved in central sensitization, aiming to elucidate the pathogenesis of neuropathic pain and provide a basis for the development of more effective treatment models.
Primary Objectives: The specific aims of this study are to 1) demonstrate that Heparin bladder instillations reduce the number of UTI episodes; 2) demonstrate Heparin bladder instillations increase median intervals between UTI; and 3) demonstrate that Heparin bladder instillations decrease urine inflammatory (NGAL) levels. Study Design: This study will be a randomized, double-blind, placebo-controlled trial of subjects treated for documented recurrent urinary tract infections with heparin bladder instillation versus sterile saline instillations. The study recruits women (n = 30) with 3 or more UTI episodes in one year from the patient population at The University of Oklahoma Health Sciences Center (OUHSC) and The University of Oklahoma-Tulsa (OU-Tulsa) and randomly assigns them to treatment as usual care with sterile saline instillation (n =15) or treatment as usual with heparin bladder instillations (n = 15). Subjects are given 6 weekly bladder instillations with interval follow-ups; the primary outcome measures are number of UTI episodes during the six month study period and a survival analysis assesses time to the next UTI. The usual care of this study is antibiotic treatment for UTI only. Urine samples will be collected at certain intervals. Analysis: We will seek a statistically significant difference of the recurrent UTI rate for 6 months between heparin instillation and sterile saline instillation group. Assuming Recurrent UTI rate of sterile saline bladder instillation is 2.3.3 UTI episodes per six months, a 35% reduction in the recurrent UTI rate is deemed significant based on previous literature. A sample size 30 (15 for each group) will achieve 60% power to detect a 35% reduction in recurrent UTI rate at a 0.05 significance level. Allowing for a 25% drop out, a total of 30 subjects will be required. Significance: Recurrent UTIs are challenging to manage, especially if microbiological results are equivocal. In women who suffer from frequent recurrences, daily antibiotic use is the most effective strategy for recurrent UTI prevention compared to daily cranberry pills, daily estrogen therapy, and acupuncture. However even with this traditional approach of continuous antibiotic for 6 to 12 months, the rate of UTI was only reduced during prophylaxis and the rate of UTI was unchanged after stopping antibiotic treatment. Increasing antibiotic resistance rates require immediate identification of innovative alternative prophylactic therapies. The lack of non-antibiotic therapies gives an opportunity to develop innovative strategies to decrease recurrent UTIs and decrease the burden of UTIs. This study will augment the current evidence available on the aggregate effects of a treatment that emphasizes the optimization of both antibiotic regimens and non-antibiotic interventions.
After the entry DBPCFC, subjects will be randomized 1:1 to active or placebo drug product. Subjects randomized to peanut SLIT therapy will dose for 36 months and undergo a second DBPCFC. The subjects will stop dosing for three months and repeat a DBPCFC at 39 months.
This study investigated the effects of training using motor imagery on balance, gait parameters, and ataxia severity in children after they underwent medulloblastoma tumour resection. Fifty participated children, aged seven-nine years and diagnosed with cerebellar ataxia after medulloblastoma resection were selected from the Tumor Hospital of Cairo University. Two groups of patients were randomly divided: the study group and the control group. The control group received a physical therapy program, whereas the study group received training in motor imagery along with a traditional physical therapy program. Each group was assessed using the Scale for the Assessment and Rating of Ataxia (SARA), Pediatric Berg Balance Scale (PBBS), and kinematic gait analysis using the Kinovea software. Significant improvements were noted in balance, ataxia, and spatial and temporal gait parameters in both groups, which favoured the study group (P > 0.05). Training in motor imagery is an effective rehabilitation treatment for medulloblastoma resection and may be applied in combination with an appropriate physical therapy.Trial registration: ClinicalTrials.gov identifier, NCT05992207, 08-07-2023.
There is widespread agreement that pain is under-treated in the Emergency Department (ED). The current recommended treatment of acute pain in the ED setting is administration of an initial bolus of morphine followed by titration until adequate analgesia is achieved. Several studies have shown that even 0.1 mg/kg IV morphine (7-10 mg administered to the average 70-100 kg patient) inadequately treats many patients' acute pain. In spite of this, it has been observed that many emergency physicians and nurses are hesitant to give 7-10 mg of morphine as an initial IV dose. In contrast, it has been observed that these same healthcare providers were not similarly reluctant to administer a roughly equianalgesic dose of hydromorphone (1-1.5 mg), perhaps because the more potent hydromorphone is given in much smaller milligram quantities than morphine, thus providing the illusion of substantially less opioid administered to the patient. Having repeatedly observed this phenomenon, it is reasonable that if a smaller milligram dose of hydromorphone were shown to provide an efficacy, safety, and side-effect profile comparable or superior to a larger milligram dose of morphine, it would provide evidence supporting use of hydromorphone as an alternative first line opioid in the treatment of acute pain presenting to the ED. As a practical corollary to this, it is reasoned further that the increased willingness of healthcare providers to use hydromorphone might contribute to reducing one component of the multifaceted problem of oligoanalgesia in the ED.